Related Experiment Video

Updated: Jun 21, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

The role of platelets CD40 ligand (CD154) in acute coronary syndromes

Mona A Abu el-Makrem1, Yehia Z Mahmoud, Douaa Sayed

  • 1Internal Medicine Department, Faculty of Medicine, El-Minia University, Egypt.

Thrombosis Research
|August 7, 2009
PubMed

Insights

Platelet CD154 levels are elevated in acute coronary syndromes (ACS), correlating with inflammation and disease severity. This suggests CD154 may indicate thrombo-embolic events and highlights nitric oxide's potential anti-atherogenic role.

Area of Science:

  • Cardiovascular Medicine
  • Immunology
  • Biochemistry

Background:

  • The biological role of CD154 on platelets is established, but its significance in stable angina and acute coronary syndrome (ACS) remains unclear.
  • Investigating CD154 expression on platelets is crucial for understanding its involvement in cardiovascular disease pathogenesis.

Purpose of the Study:

  • To examine the expression of CD154 on platelets in patients with ACS.
  • To determine the relationship between platelet CD154 levels and clinical parameters in ACS patients.

Main Methods:

  • Flow cytometry was used to analyze CD154 and CD62 expression on platelets.
  • The study cohort included patients with ACS (acute myocardial infarction and unstable angina), stable angina, and healthy volunteers.
  • Correlations between platelet markers and clinical/laboratory data were assessed.

Main Results:

  • Elevated platelet CD154 and CD62 levels were observed in patients with acute myocardial infarction (AMI) and unstable angina (UA) compared to stable angina (SA) and healthy controls.
  • Platelet CD154 positively correlated with pro-inflammatory markers (Ox-LDL, CRP, fibrinogen), wall motion score, and cardiovascular risk factors.
  • A negative correlation was found between platelet CD154 and serum nitric oxide levels.

Conclusions:

  • CD154 on platelets may serve as a biomarker for thrombo-embolic events in ACS.
  • Nitric oxide may possess anti-atherogenic properties, warranting further investigation.
  • Platelet activation is associated with the severity of coronary artery disease in ACS patients.
Abstract

More Related Videos

Intravital Microscopy of Leukocyte-endothelial and Platelet-leukocyte Interactions in Mesenterial Veins in Mice05:12

Intravital Microscopy of Leukocyte-endothelial and Platelet-leukocyte Interactions in Mesenterial Veins in Mice

Published on: August 13, 2015

Real-time Imaging of Heterotypic Platelet-neutrophil Interactions on the Activated Endothelium During Vascular Inflammation and Thrombus Formation in Live Mice11:18

Real-time Imaging of Heterotypic Platelet-neutrophil Interactions on the Activated Endothelium During Vascular Inflammation and Thrombus Formation in Live Mice

Published on: April 2, 2013

Related Concept Videos

Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.